Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Healthy Adult Participants 1Gastrointestinal Stromal Tumors 1Diabetes Mellitus, Type 2 1Advanced Solid Tumor 1

Interventions

toripalimab 6Injections 4tislelizumab 3sintilimab 3pembrolizumab 3cediranib 3glumetinib 2apatinib 2PM 01183 2Midazolam 2Irinotecan 2Gemcitabine 2Drug Therapy 2Digoxin 2Bupropion 2talazoparib 1spartalizumab 1sonidegib 1sitravatinib 1serabelisib 1sapanisertib 1rucaparib 1repaglinide 1penpulimab 1palbociclib 1lenvatinib 1fluzoparib 1erdafitinib 1entrectinib 1dactolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Solid Tumor × repaglinide × Clear all
NCT04457180 2022-10-26

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
18 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡